96524-70-8

Usage

Uses

Used in Fragrance Industry:
Methyl(p-formylphenyl)acetate is used as a flavoring agent and fragrance in consumer products such as perfumes, soaps, and cosmetics. Its fruity scent is utilized to impart a fruity or floral aroma to these products.
Used in Food Industry:
Methyl(p-formylphenyl)acetate is also commonly used in the production of food flavorings. It is considered safe for consumption in small quantities and contributes to enhancing the taste and aroma of various food items.

Upstream product

• 72770-09-3 4-(chloromethyl)-phenylacetic methylester 
• 155380-11-3 methyl 4-(hydroxymethyl)phenylacetate 
• 17833-56-6 ester monomethylique de l'acide p-phenylene diacetique 
• 52798-01-3 methyl 4-cyanobenzeneacetate 
• 101-41-7 benzeneacetic acid methyl ester 
• 73401-74-8 4-hydroxymethylphenylacetic acid 
• 75-36-5 acetyl chloride 
• 7398-42-7 methyl 2-(4-(bromomethyl)phenyl)acetate 
• 13737-36-5 4-bromophenylacetic acid 
• 147283-85-0 (4-Trifluoromethanesulfonyloxy-phenyl)-acetic acid methyl ester 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 156-38-7 4-hydroxyphenylacetate 

Downstream Products

• 808753-10-8 [4-(2-cyano-vinyl)-phenyl]-acetic acid methyl ester 
• 854778-03-3 methyl {4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amino)methyl]phenyl}acetate 
• 854776-39-9 methyl {4-[({3-[3-methyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amino)methyl]phenyl}acetate 
• 854778-07-7 [4-({[3-(3-benzoyl-8-methylquinolin-4-yl)phenyl]amino}methyl)phenyl]acetic acid methyl ester 
• 1080008-24-7 methyl 2-(4-((3-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)propylamino)methyl)phenyl)acetate 
• 1080007-27-7 methyl [4-({[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl][2-(dimethylamino)ethyl]amino}methyl)phenyl]acetate 
• 1158802-27-7 methyl 2-(4-((3-(2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)propylamino)methyl)phenyl)acetate 
• 1613414-62-2 methyl 2-(4-(1,3-dioxolan-2-yl)phenyl)acetate 
• 7398-47-2 methyl 2-(4-(1-hydroxyethyl)phenyl)acetate 
• 927187-42-6 (4-{4-[2-(2,4-dichloro-phenoxy)-ethylcarbamoyl]-5-phenyl-isoxazol-3-yl}-phenyl)-acetic acid methyl ester 
• 854766-05-5 {4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amino)methyl]phenyl}acetic acid 

Relevant academic research and scientific papers

Chemoselective Deoxygenation of 2° Benzylic Alcohols through a Sequence of Formylation and B(C6F5)3-Catalyzed Reduction

A sequence of formylation and B(C6F5)3-catalyzed reduction of the resulting formate with Et3SiH enables the chemoselective deoxygenation of secondary benzylic alcohols. Primary benzylic and tertiary non-benzylic alcohols are not reduced by this protocol. The formyl group fulfills a double role as activator and self-sacrificing protecting group. The deoxygenation of these formates is fast and can be carried out in the presence of other potentially reducible groups. Neighboring-group participation was found in the deoxygenation of certain diol motifs.

IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME

Imidazole-based anticancer agents and derivatives thereof, as well as methods of making and methods of using the same, are described. The imidazole-based anticancer agents are HDAC inhibitor compounds having a 1-(1H-imidazol-2-yl)ethan-1-one or 1-(1H-imidazol-2-yl)ethane-1- thione moiety.

OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Compounds of formula (I) described herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

PURINE DERIVATIVES

The invention provides the compound of formula. (I) and pharmaceutically acceptable salt thereof, pharmaceutical compositions containing the compound and the use of the compound in therapy.

BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS

The present invention relates to compounds according to formula (I) , a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta2 adrenoreceptor agonists.